{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06126796",
            "orgStudyIdInfo": {
                "id": "MDT-CxB-01"
            },
            "secondaryIdInfos": [
                {
                    "id": "23-008567",
                    "type": "OTHER",
                    "domain": "Mayo Clinic Institutional Review Board"
                },
                {
                    "id": "NCI-2023-09278",
                    "type": "REGISTRY",
                    "domain": "Clinical Trials Reporting Program (CTRP)"
                }
            ],
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)",
            "officialTitle": "A Randomized Cross-Over Study to Evaluate Patient Preference and Satisfaction With Urine-based Molecular Testing Versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "urine-based-molecular-testing-vs-cystoscopy-for-surveillance-of-nonmuscle-invasive-bladder-cancer-nmibc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-07",
            "studyFirstSubmitQcDate": "2023-11-07",
            "studyFirstPostDateStruct": {
                "date": "2023-11-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Mark D. Tyson II, M.D., M.P.H.",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra."
        },
        "conditionsModule": {
            "conditions": [
                "Non-muscle Invasive Bladder Cancer"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 107,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A: CxBladder followed by cystoscopy",
                    "description": "Arm A will undergo testing with CxBladder 3 months after randomization followed by a cystoscopy 3 months thereafter",
                    "interventionNames": [
                        "Diagnostic Test: CxBladder Monitor",
                        "Diagnostic Test: Cystoscopy"
                    ]
                },
                {
                    "label": "Arm B: cystoscopy followed by CxBladder",
                    "description": "Arm B will undergo cystoscopy 3 months after randomization followed by testing with CxBladder 3 months thereafter.",
                    "interventionNames": [
                        "Diagnostic Test: CxBladder Monitor",
                        "Diagnostic Test: Cystoscopy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "CxBladder Monitor",
                    "description": "CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.",
                    "armGroupLabels": [
                        "Arm A: CxBladder followed by cystoscopy",
                        "Arm B: cystoscopy followed by CxBladder"
                    ],
                    "otherNames": [
                        "CxBladder",
                        "CxbM"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Cystoscopy",
                    "description": "Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.",
                    "armGroupLabels": [
                        "Arm A: CxBladder followed by cystoscopy",
                        "Arm B: cystoscopy followed by CxBladder"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Preference for CxBladder Monitor compared to cystoscopy",
                    "description": "Patient preference will be assessed based on the Preference Questionnaire (PQ) after completion of the study cross-over period (after both methods of testing have been experienced).",
                    "timeFrame": "Up to 6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Patient satisfaction",
                    "description": "Patient satisfaction will be assessed based on the Satisfaction Questionnaire (SQ) after completion of each test at 3 and 6 months.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Change in symptoms and function - EORTC NMIBC-24",
                    "description": "The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Non-Muscle-Invasive Bladder Cancer (EORTC NMIBC-24) will be used to assess Health-related quality of life. The questionnaire consists of 24 items scored on a four-point Likert scale ranging from 1 (not at all) to 4 (very much), with the exception of the global health status items, which employ a seven-point scale ranging from 1 (very poor) to 7 (excellent). Higher scores are interpreted as more symptom burden, with exception of the sexual function and sexual enjoyment sections, where higher scores represent better functioning.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Fear of Cancer Recurrence Inventory- Short Form (FCRI-SF)",
                    "description": "Health-related quality of life will be assessed based on the Fear of Cancer Recurrence Inventory- Short Form (FCRI-SF) at baseline, 3 months (within 1 week of test), and 6 months (within 1 week of test). The nine-item FCRI evaluates the presence and severity of intrusive thoughts associated with FCR. Each item is rated on a Likert scale ranging from 0 (\"not at all\" or \"never\") to 4 (\"a great deal' or \"all the time\"). A higher score indicates higher levels of FCR.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Financial costs",
                    "description": "Assessed by patient responses to questions about missed work and time missed from usual activities.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Error rate identifying recurrent nonmuscle invasive bladder cancer (NMIBC)",
                    "description": "Error rate for CxBladder is defined as the proportion of patients who have a negative CxBladder at 3 months but have a recurrence identified on cystoscopy at 6 months for patients in arm A. The error rate for cystoscopy is defined as the proportion of patients who have a negative cystoscopy at 3 months but have a positive CxBladder at 6 months that is subsequently confirmed by cystoscopy for patients in arm B.",
                    "timeFrame": "Up to 6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence.\n* Able to provide urine for testing and comply with study protocol.\n* Have an email address and be willing to complete surveys online.\n\nExclusion Criteria:\n\n* History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma)\n* Patients with predominant (\\>50%) variant histology\n* Patients with a history of upper tract and/or urethral cancer\n* Women who are pregnant",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Male or female adult patients who are undergoing cystoscopic surveillance for NMIBC after at least 9 months of recurrence-free survival.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Referral Office",
                    "role": "CONTACT",
                    "phone": "855-776-0015",
                    "email": "mayocliniccancerstudies@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mark D. Tyson, M.D., M.P.H.",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Arizona",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85259",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Mark D. Tyson, M.D., M.P.H.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001749",
                    "term": "Urinary Bladder Neoplasms"
                },
                {
                    "id": "D000093284",
                    "term": "Non-Muscle Invasive Bladder Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "asFound": "Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2976",
                    "name": "Non-Muscle Invasive Bladder Neoplasms",
                    "asFound": "Non-muscle Invasive Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T4202",
                    "name": "Oculocerebral Syndrome With Hypopigmentation",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}